Black Diamond 10-Q: $102M Cash Into H2 2028, Q3 Net Loss $10.0M
BDTX sits 25% above its 52-week low of $1.6.
Summary
Black Diamond's Q3 10-Q shows a $10.0 million quarterly net loss and $102.0 million in cash and investments, enough to fund operations into the second half of 2028 — before the Phase 3 trial that will require substantial new capital.
Key Events · Earnings and Guidance · BDTX
-
Q3 Net Loss of $10.0 Million
The three-month net loss was $10.0 million ($0.17 per share) versus $8.5 million a year earlier; for the nine months, the net loss was $29.0 million against net income of $37.5 million in 2025, which included the $70.0 million Servier upfront.
-
$102.0M Cash Funds Operations Into H2 2028
Cash, cash equivalents and investments totaled $102.0 million at September 30, 2026, down from $128.7 million at year-end 2025; management guides this funds planned operations into the second half of 2028.
-
Phase 3 Still Needs Substantial New Capital
The filing states the company will need to raise substantial additional capital to initiate and complete the Phase 3 trial in frontline EGFR-NCM NSCLC, planned to start in Q2 2027 pending Cohort 4 safety data submission to FDA.
-
R&D Down, G&A Up Year Over Year
Nine-month R&D fell to $21.4 million from $27.3 million as NSCLC trial costs declined $7.4 million, offset by $6.5 million of new GBM spending; G&A rose to $14.1 million from $12.6 million on higher IP-related and non-income tax expense.
Analysis · BDTX · Life Sciences
The clinical headline was already out this morning; what's new here is the money. Black Diamond ended September with $102.0 million in cash and investments, a balance it says funds operations into the second half of 2028 — a runway that comfortably covers the planned Q2 2027 Phase 3 start, though management states plainly it will need to raise substantial additional capital to run and complete that trial. The quarter itself was a $10.0 million net loss, and nine-month R&D fell to $21.4 million from $27.3 million as NSCLC spending wound down while the GBM program ramped up $6.5 million. G&A rose to $14.1 million from $12.6 million on IP and non-income tax costs. No going-concern language, no financing executed in the period — the ATM added nothing in Q3.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDTX was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.